A Clinician’s Guide to Collaborating with the Neurotechnology Industry

For clinicians who treat patients with neurotechnologies, staying updated on the latest advancements and collaborative efforts with industry is crucial for enhancing patient care. Understanding the dynamics of industry partnerships can help you leverage cutting-edge neurotechnology innovations effectively.

This article explores how industry partnerships facilitate development of groundbreaking neurotechnologies and ultimately improve clinical outcomes. By cultivating mutually beneficial interactions with industry, you can better navigate the complexities of neurotechnology deployment and contribute to the advancement of patient treatment in your practice.

What are Neurotechnologies?

Neurotechnologies encompass a range of devices and methodologies designed to interact with the nervous system to diagnose, monitor, and treat neurological and psychiatric disorders. A major advantage of neurotechnology is its potential to improve treatment outcomes and the quality of life for patients with severe chronic conditions, including Parkinson’s disease, epilepsy, multiple sclerosis, hearing or visual impairments, or mood disorders. These technologies can be either physically invasive or non-invasive:

Invasive neurotechnologies include devices that are surgically implanted directly into the body, such as deep brain stimulators (DBS) or brain-computer interfaces (BCI).
Non-invasive neurotechnologies involve devices external to the body, such as transcranial magnetic stimulators (TMS) and transcranial direct current stimulators (tDCS), which can monitor and influence brain activity without the need for surgery.

What are Industry-Academic Partnerships?

A vital pathway for the research and development of neurotechnologies are through industry-academic (IA) partnerships—collaborations between universities and companies aimed at bringing novel neurotechnologies into clinical care settings, enhancing patient treatment options and outcomes. Clinicians working with these technologies need strong relationships with the companies to access, maintain, and use devices effectively in their practice.

Clinicians often collaborate with both industry and academic institutions (e.g., academic medical centers) to inform device development through user experience research, act as clinical trial sites, and provide ongoing patient data. These contributions are critical as scientists in both industry and academia continue to innovate and refine neurotechnologies for widespread clinical use.

IA partnerships can take various forms, involving a mix of scientific, regulatory, and commercial responsibilities—distributed across researchers, university administrators, company staff, clinicians, and sometimes patients. Examples of how IA partnerships form include:

University-Initiated Partnerships: University scientists discover or design new neurotechnologies and seek company partners to help develop and commercialize them.
Industry-Initiated Collaborations: Companies identify promising university labs or researchers and offer funding or licensing opportunities to support neurotechnology development.
Spinouts and Startups: Academic researchers or clinicians may launch companies to translate their neurotechnology innovations into practice, often remaining embedded in both commercial and academic worlds.
Collaborative Clinical Trials: Partnerships may also form around device testing, with industry partners supporting clinical trials or co-developing protocols.
Regulatory and Commercialization Support: Universities may assist with early-stage innovation, while industry guides FDA approval and market entry.

How do Industry Partnerships Impact Clinical Care?

Partnerships with the neurotechnology industry also present unique challenges and shape the clinical environment in a way that must be addressed to maximize patient benefit and minimize harm and risk. Examples of these challenges include:

Patient Communication & Informed Consent: Patients have informational needs. Clinicians must ensure clear communication about neurotechnology capabilities and limitations, especially for patients with impaired cognitive or decision-making capacity. Some patient populations may struggle to fully grasp the benefits, risks, side effects, and impact on daily living related to these technologies.Use comprehensive communication strategies to explain risks, side effects, alternative treatments, the nature of industry and academic involvement, financial implications, and plans for long-term care and device maintenance.

Read more: Patient Consultation, Communication, and Managing Public Perceptions about Neurotechnology

Post-Trial Access & Continuity of Care: Clinicians play a key role in proactively ensuring safe, continuous access to neurotechnologies, including post-trial device access and managing situations like company insolvency, device discontinuation, or device component replacement.While FDA pathways exist, preserving post-trial access to neurotechnologies needs greater national and international Addressing financial, legal, and clinical responsibilities for long-term care requires collaborative planning. Engage with industry and academic partners to ensure sustained patient access to neurotechnologies.

Read more: Continuity of Care for the Long-term

Managing Conflicts of Interest & Unconscious Bias: Clinicians must collaborate with industry to effectively use and contribute to the development and refinement of neurotechnologies. However, relationships and interactions with industry representatives can insert bias into clinicians’ information gathering, idea evaluation, and decision-making. Biases are a normal part of being human and can happen unconsciously.Balancing industry relationships with risks related to conflicts of interest—or even the appearance of such conflicts—is crucial. Clinicians often have multiple roles as physicians, researchers, and business owners who have a vested interest in the intellectual property of a device. This role conflict complicates management of conflicts of interest. Clinicians need to be intentional in managing and mitigating sources of bias to prioritize patient care and professional integrity.

Read more: Navigating Interactions with the Neurotechnology Industry: Guidance for Clinicians

Finding Robust Data on New Neurotechnologies: Clinicians need to obtain comprehensive information on device efficacy, side effects, and financial implications to make informed decisions about neurotechnology use for clinical care. Companies often protect proprietary information, making it difficult for clinicians to access detailed and unbiased data about the technology to determine if it is appropriate for clinical care.When searching for information about a neurotechnology, clinicians may encounter incomplete or inaccessible data from publications and other company resources. We encourage clinicians to prioritize industry partnerships with transparent companies, encourage industry partners to share complete safety and efficacy data, and consult third-party reviews and independent research on a neurotechnology to supplement information provided by the company.

Read more: Evaluating Neurotechnology for Clinical Care

Neural Data Protection: Neurotechnologies can interpret and alter brain activity related to perception, behavior, emotion, cognition, and memory. The magnitude of change neurotechnology can have on a patient raises important questions about data privacy, misuse, and risks of stigmatization and discrimination.Given the sensitive nature of neural data, clinicians must take proactive steps to ensure data privacy and address potential misuse. Review vendor agreements for privacy provisions, educate patients about data security, and implement and continuously monitor robust data security measures in your practice.

Read more: Neural Data: Ensuring Proper Security and Responsible Use

In Summary

Advancing neurotechnology through industry partnerships requires thoughtful engagement from clinicians to foster responsible innovation, maximize benefits, and minimize harms for patients. Addressing issues such as neural privacy, informed consent, data governance, bias, conflicts of interest, and continuity of device access is vital to uphold the needs and well-being of patients and research participants. Playing an active, collaborative role in partnerships with industry and academia is crucial for clinicians to effectively enhance their patients’ care and health outcomes.

JUMP TO:

RELATED ARTICLES:

Navigating Interactions with the Neurotechnology Industry: Guidance for Clinicians
Evaluating Neurotechnology for Clinical Care
Patient Consultation, Communication, and Managing Public Perceptions about Neurotechnology

DOWNLOADABLE RESOURCES